Journal of Medicinal Chemistry p. 4913 - 4925 (2016)
Update date:2022-07-29
Topics:
Wang, Heng-Yen
Qin, Yajuan
Li, Huiying
Roman, Linda J.
Martásek, Pavel
Poulos, Thomas L.
Silverman, Richard B.
Neuronal nitric oxide synthase (nNOS) is an important therapeutic target for the treatment of various neurodegenerative disorders. A major challenge in the design of nNOS inhibitors focuses on potency in humans and selectivity over other NOS isoforms. Here we report potent and selective human nNOS inhibitors based on the 2-aminopyridine scaffold with a central pyridine linker. Compound 14j, the most promising inhibitor in this study, exhibits excellent potency for rat nNOS (Ki = 16 nM) with 828-fold n/e and 118-fold n/i selectivity with a Ki value of 13 nM against human nNOS with 1761-fold human n/e selectivity. Compound 14j also displayed good metabolic stability in human liver microsomes, low plasma protein binding, and minimal binding to cytochromes P450 (CYPs), although it had little to no Caco-2 permeability.
View MoreWuhan Shangrisyn chemicals Technology Co.,Ltd(expird)
Contact:+86-027-84466317 __ +86-15387123698
Address:wuhan - china
Contact:+49-4101-3053-0
Address:Waldhofstrasse 14 ,25474 Ellerbek Germany
FOSHAN NANHAI ZHONGNAN PHARMACEUTICAL FACTORY
Contact:0086-0757-85609331
Address:XIAHENGTIAN INDUSTRIAL ZONE,SHAYONG VILLAGE,LISHUI TOWN
Jiangsu Feymer Technology Co., Ltd.
Contact:+86-512-58110132
Address:Fenghuang Town, Zhangjiagang City, Jiangsu Province, China
BAODING SINO-CHEM INDUSTRY CO.,LTD
Contact:0312-5956088
Address:NO.8 FUXING ROAD,CHINA
Doi:10.1055/s-2001-16773
(2001)Doi:10.1002/chem.201304063
(2014)Doi:10.1039/f19827800347
(1982)Doi:10.1016/S0040-4039(01)84944-3
(1972)Doi:10.1021/ja01609a033
(1955)Doi:10.1016/j.jinorgbio.2010.03.013
(2010)